Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on September 8, 2023, covering the event date of September 1, 2023. The company is incorporated in Delaware and operates as an emerging growth company. The filing primarily addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the departure of a director and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the resignation of Dr. Michael H. May from the Board of Directors. Dr. May, who serves as President and CEO of CCRM and CCRM Enterprises Inc., informed the company he will not stand for re-election at the next annual meeting expected in December 2023. He serves on the Audit, Compensation, and Nominating and Corporate Governance Committees. The company stated the departure is due to Dr. May's need to reduce external commitments and explicitly noted there was no disagreement regarding the company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in other SEC filings. No specific business guidance, outlook, or new risk contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the composition of the Board of Directors following Dr. May's resignation.
- Confirm the status of the Audit, Compensation, and Nominating and Corporate Governance Committees to ensure quorum and compliance.
- Review the company's upcoming annual meeting schedule for the election of a replacement director.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.